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ABSTRACT 
 
Weil, Brian Raymond (Ph.D., Integrative Physiology) 
Vascular Consequences of Prehypertension 
Dissertation directed by Professor Christopher A. DeSouza, Ph.D. 
 
  
Prehypertension, defined as systolic blood pressure between 120-139 mm Hg and/or 
diastolic blood pressure between 80-89 mm Hg, is a common condition that affects ~30% of the 
US adult population.  It is increasingly recognized that prehypertension is not only an 
independent risk factor for the development of clinical hypertension (blood pressure ≥ 140/90 
mm Hg), but also cardiovascular disease and its clinical consequences, such as myocardial 
infarction, stroke, and congestive heart failure. The increased cardiovascular risk associated with 
prehypertension may be mediated, at least in part, by vascular endothelial dysfunction, a critical 
etiological event in the pathogenesis and progression of atherosclerotic vascular disease.  
However, the impact of blood pressure in the prehypertensive range on the vascular endothelium 
is currently unclear.  Accordingly, the purpose of this dissertation was to determine: 1) if 
prehypertension is associated with impaired nitric oxide (NO)-mediated endothelium-dependent 
vasodilation; 2) whether endothelin (ET)-1 vasoconstrictor tone is elevated in prehypertensive 
adults; and, if so, 3) whether the increase in ET-1-mediated vasoconstriction contributes to 
endothelial vasodilator dysfunction in prehypertensive adults. To address these aims, venous 
occlusion plethysmography was used to measure forearm blood flow responses to intra-arterial 
acetylcholine, sodium nitroprusside, and selective and non-selective ET-1 receptor blockade in 
normotensive and prehypertensive adults.  In addition, forearm blood flow responses to 
acetylcholine were determined with concomitant endothelial NO synthase inhibition and 
selective ET-1 receptor blockade.  The results of these studies indicate that: 1) prehypertension is 
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associated with impaired NO-mediated endothelium-dependent vasodilation; 2) ET-1 
vasoconstrictor tone is greater in prehypertensive compared with normotensive adults; and 3) the 
elevation in ET-1-mediated vasoconstriction contributes to impaired endothelium-dependent 
vasodilation with prehypertension.  Collectively, these findings demonstrate that blood pressure 
in the prehypertensive range, independent of other cardiovascular risk factors, is associated with 
impaired endothelial vasomotor function.  Reduced NO-mediated endothelium-dependent 
vasodilation and elevated ET-1-mediated vasoconstrictor tone represent an atherogenic 
endothelial phenotype that may contribute to the elevated risk of clinical hypertension and acute 
vascular events in prehypertensive adults. 
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2 
Introduction 
Hypertension, defined as systolic blood pressure (BP) ≥ 140 mm Hg systolic and/or 
diastolic BP ≥ 90 mm Hg, is a major cardiovascular disease (CVD) risk factor that affects more 
than 25% of the worldwide adult population, with projections that this number will increase to 
~30% by the year 2025 (1).  Elevated BP in the hypertensive range is estimated to cause 7.1 
million deaths each year, which accounts for 13% of all global deaths (2).  Hypertension is a 
primary risk factor for premature cardiovascular and cerebrovascular morbidity and mortality (3-
5).  Furthermore, the World Health Organization has estimated that ~62% of cerebrovascular 
disease and ~49% of ischemic heart disease worldwide can be attributed to elevated BP levels 
(2).  In the United States, one in three adults has hypertension (6) and the direct and indirect 
medical costs of high blood pressure in 2009 were approximately $73.4 billion (7).  Due to the 
high prevalence of hypertension and the significant health risks and medical costs associated 
with this condition, it has been suggested that high BP is the most important modifiable risk 
factor for cardiovascular, cerebrovascular, and renal disease (8,9).   
 In an attempt to assist clinicians in diagnosis, vascular risk assessment, and management 
of patients with elevated BP, the United States Joint National Committee on the Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure (JNC) and other international 
societies have categorized BP into discrete categories.  The thresholds that have defined 
hypertension have evolved since the initial JNC report in 1976 due to the accumulation of new 
observational and epidemiologic data.  While the first JNC report stated that adults with BP 
between 140/90 and 160/95 mm Hg should be monitored without specific treatment depending 
on age, it was not until JNC III, published in 1984, that it had become clear that a BP higher than 
140/90 mm Hg required treatment, regardless of age (10).  This threshold for hypertension has 
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remained in place throughout subsequent JNC reports, despite other changes in classification and 
treatment guidelines.  However, several large observational investigations have demonstrated a 
continuous relation between elevated BP and cardiovascular risk that begins at BP ranges well-
below the hypertension threshold of 140/90 mm Hg (5,11,12).  For example, results from a 
worldwide meta-analysis of almost 1 million adults indicate that the risk of cardiovascular death 
doubles with every 20/10 mm Hg elevation in BP, starting at 115/75 mm Hg (5).  As a reflection 
of the linear relation between elevated BP and cardiovascular risk, the guidelines set forth by the 
seventh and most recent report from the JNC include a new category termed “prehypertension” 
to describe individuals with a systolic BP between 120 and 139 mm Hg and/or a diastolic BP 
between 80 and 89 mm Hg (3). 
The addition of the prehypertension category to the JNC guidelines was made in an effort 
to alert the public and health care providers to the increased risk associated with elevated BP 
levels, even at ranges that were previously considered normal (13).  However, the new 
classification guidelines were not universally accepted; other international societies formulating 
guidelines for high BP did not adopt the term “prehypertension” into their recommendations (14-
17).  Furthermore, the addition of prehypertension to the JNC guidelines stimulated debate 
regarding the necessity for revising the classification system and the health impact of BP in the 
prehypertensive range (18).  Nevertheless, those involved in formulating the JNC VII guidelines 
have stood by the consistent finding that prehypertensive individuals are at a greater risk of 
developing hypertension and experiencing adverse cardiovascular consequences (13). 
A large body of evidence suggests that damage and dysfunction of the vascular 
endothelium is a key mechanism by which elevated BP promotes the development and 
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progression of atherosclerotic vascular disease (19).  Indeed, hypertension is associated with 
abnormal endothelial function in the peripheral, coronary, and renal circulation (20-22).  
However, the impact of BP in the prehypertensive range on the vascular endothelium is currently 
unknown.  Insight into the influence of prehypertension on endothelial function would provide a 
greater understanding of the mechanisms responsible for the increased risk of CVD in this 
population, as well as reinforce the importance of alerting society to the negative health 
implications of BP in the prehypertensive range.  
Prehypertension 
Epidemiology 
 Prehypertension is a common condition in the US and other countries (23).  Data from 
the 2005-2006 National Health and Nutrition Examination Survey (NHANES) indicate that 
~25% of the US population above 20 years of age has prehypertension, including ~32 million 
men and ~21 million women (24).  Other estimates of the prevalence of prehypertension in the 
US are even higher; there is evidence from the Framingham Heart Study that 43% of men and 
39% of women between the ages of 35 and 63 years have BP in the prehypertensive range (25).  
The prevalence of prehypertension is similar across ethnicities, with only small variations 
between non-Hispanic whites (31.2%), non-Hispanic blacks (30.4%), Mexican-Americans 
(30.9%), and other ethnic groups (31%) (26).  As with hypertension, prehypertension is 
commonly found in association with other traditional cardiovascular risk factors, particularly 
smoking, diabetes, obesity, and dyslipidemia (11,12,27,28).  In addition to these traditional risk 
factors, several novel biomarkers are elevated in people with prehypertension, including markers 
of inflammation such as C-reactive protein and tumor necrosis factor-α (29-31).  
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Cardiovascular Risk 
Individuals with prehypertension are at a greater risk of progressing to hypertension than 
those who are normotensive.  Data from the Framingham Heart Study indicate that the four-year 
risk of developing hypertension for individuals aged 35-65 years is 18% for those with baseline 
BP 120-129/80-84 mm Hg  (lower prehypertensive range) and 37% for those with BP 130-
139/85-89 mm Hg  (upper prehypertensive range), compared with 5% for subjects with normal 
BP (32).  Corresponding rates of developing hypertension for adults aged 65 years and older 
were 26% and 50% in the lower prehypertensive range and upper prehypertensive range, 
respectively (32).  Similar results were observed in a longitudinal study of over 2,000 British 
adults, which found that the risk of developing hypertension over a 7-year follow up period was 
two-fold greater for those in the lower prehypertensive range and 2.9-fold higher for those in the 
upper prehypertensive range compared with normotensive individuals (33).  These findings of an 
increased risk of hypertension in prehypertensive individuals have been supported by several 
other investigations (25,34,35), providing support for the fact that prehypertensive adults are 
more likely to become hypertensive than normotensive adults. 
In addition to the increased risk of progressing to hypertension, prehypertension is now 
considered to be an independent risk factor for CVD.  Prior to publication of the JNC VII 
guidelines, Vasan and colleagues found that high-normal BP (i.e., 130-139/85-90 mm Hg; from 
the JNC VI guidelines) is an independent risk factor for major cardiovascular events, including 
myocardial infarction, stroke, and congestive heart failure (12).  High-normal BP was associated 
with a significantly elevated hazard ratio for CVD of 2.5 in women (95% confidence interval 
(CI): 1.6 - 4.1) and 1.6 in men (95% CI: 1.1 – 2.2), even after adjustment for other cardiovascular 
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risk factors.  Furthermore, the ten year absolute risk for a major cardiovascular event in 
individuals with high-normal BP above the age of 65 years was ~20% in both men and women 
(12).  More recently, prehypertension was independently associated with an increased risk of 
CVD after an eighteen-year observation period in participants of NHANES I (1971-1975) (11).  
After adjustment for traditional CVD risk factors, including age, body mass index, and history of 
cigarette smoking, prehypertensive subjects had a 32% higher risk for major CVD events 
compared with those with normal BP (11).  In the Women’s Health Initiative study, ~40% of the 
60,785 postmenopausal women studied were prehypertensive and, after an eight year follow-up 
period, these women had a significantly higher risk of myocardial infarction (76%), stroke 
(93%), heart failure (36%), and cardiovascular death (58%) compared to normotensive women 
(36). Finally, Qureshi and colleagues found that prehypertension was significantly associated 
with an increased risk of coronary artery disease and myocardial infarction after a ten-year 
follow-up period (25).  Strikingly, the population-attributable risk associated with 
prehypertension was 47% for myocardial infarction and 20% for coronary artery disease, nearly 
all of which was due to elevated systolic BP (25). These data emphasize the significant public 
health impact of prehypertension and the risk of CVD in this population.   
Prehypertension is also associated with accelerated progression of atherosclerosis (37) 
and elevated markers of subclinical CVD (38-40).  Data from the Coronary Artery Risk 
Development in Young Adults (CARDIA) study indicate that the development of 
prehypertension between the ages of 18 and 35 is associated with greater levels of coronary 
artery calcium, which is also a strong predictor of future coronary heart disease, after a twenty 
year follow-up period (39).  In addition, individuals with “borderline hypertension” (BP = 130-
140/85-90 mm Hg) have a greater intima-media thickness of the carotid and brachial arteries 
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compared with subjects with a BP less than 130/85 mm Hg (40).  Using JNC VII guidelines, 
Manios and colleagues measured intima-media thickness in individuals with prehypertension and 
normal BP. Prehypertensive individuals had a higher carotid artery intima-media thickness and a 
greater left ventricular mass than subjects with normal blood pressure, indicating that the 
atherosclerotic burden associated with high BP begins to develop during the prehypertensive 
state (38).  
However, not all studies have found prehypertension to be an independent CVD risk 
factor.  Mainous and colleagues (41) found prehypertension to be associated with a significant 
risk of all-cause and CVD-related mortality only in individuals below the age of 55 years.  
Furthermore, prehypertension was no longer associated with a significant increase in risk when 
the authors controlled for baseline cardiovascular risk factors and markers for concomitant CVD 
(41).  Similarly, Lee et al. (42) recently published data from the Singapore Cardiovascular 
Cohort Study indicating that prehypertension is only associated with an increased risk of all-
cause or CVD-related mortality in the presence of diabetes, smoking, or pre-existing CVD.  
These findings have fueled debate regarding the cardiovascular risks associated with 
prehypertension, and it remains controversial as to whether prehypertensive BP alone or its 
common association with other CVD risk factors is responsible for the increased risk observed in 
this population 
Summary 
The inclusion of prehypertension in the guidelines set forth by the JNC VII identifies a 
new population of individuals at a higher risk for developing CVD.  In a majority of 
epidemiological studies, prehypertension has been shown to be an independent risk factor for 
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CVD, in addition to being associated with a higher risk of developing hypertension.  
Furthermore, evidence of elevated markers of subclinical CVD in individuals with 
prehypertension provides compelling evidence to suggest that the development of atherosclerotic 
vascular disease associated with high BP occurs prior to the progression to essential 
hypertension.  However, evidence that prehypertension is only associated with increased risk in 
the presence of other CVD risk factors has encouraged debate as to whether prehypertensive BP 
alone is harmful to the cardiovascular system. 
The Vascular Endothelium 
 The mechanisms contributing to the development of atherosclerotic vascular disease are 
largely mediated through damage to the vascular endothelial monolayer, resulting in its 
dysfunction (43).  The vascular endothelium is a monolayer of cells that lines the luminal surface 
of blood vessels.  Originally considered to be simply a passive interface between the blood and 
tissues, the vascular endothelium is now recognized as a metabolically active layer of cells that 
serve several structural, metabolic, and signaling functions that maintain vascular homeostasis 
(43).  Healthy endothelium is capable of sensing physical and chemical stimuli and responding to 
these factors by generating a wide range of substances that modulate vasomotor tone and 
hemostatic balance, protect the vessel from potentially harmful substances circulating in the 
blood, and regulate innate and adaptive immunity (44).  Thus, the normal vascular endothelium 
provides a protective, non-thrombogenic surface with homeostatic vasomotor and anti-
inflammatory properties (43).   
Due to its location and exposure to pathogenic stimuli in the circulating blood, the 
endothelium is a primary target for injury (43).  Endothelial injury can increase cell permeability, 
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alter the release of vasoactive substances, and interfere with its inherent anti-thrombotic 
properties (45,46).  This impairment of function represents one of the earliest events in the 
pathogenesis of atherosclerotic vascular disease, and contributes to plaque progression and 
thrombus formation (47,48).  Therefore, maintenance of endothelial function is essential in 
preventing the development and progression of atherosclerotic disease. Vasomotor control and 
fibrinolytic regulation are two key components of vascular endothelial function and play an 
integral role in maintaining the vasoprotective and thromboresistant properties of the 
endothelium (44,49).  
 
Endothelial Vasomotor Function: Role of Nitric Oxide 
Regulation of vasomotor tone is a key function of the vascular endothelium and is 
accomplished through the synthesis and release of substances that modulate contraction and 
relaxation of vascular smooth muscle cells (VSMC) in the underlying medial layer of blood 
vessels. 
Endothelium-dependent vasodilation occurs primarily through the secretion of nitric 
oxide (NO), prostacyclin, and endothelium-derived hyperpolarizing factor (EDHF).  NO is the 
primary regulator of endothelium-dependent vasodilation and plays a particularly important role 
in maintaining the health of the vessel wall (47). NO is a labile, lipid-soluble gas synthesized in 
endothelial cells (ECs) from the amino acid L-arginine via the action of endothelial NO synthase 
(eNOS) (50).  Physiologic (e.g., shear stress) and pharmacologic (e.g., thrombin, acetylcholine) 
stimuli are capable of increasing enzymatic activity of eNOS via increases in intracellular [Ca2+].  
Following diffusion from ECs to VSMCs, NO activates guanylate cyclase, resulting in increased 
intracellular concentrations of cyclic guanosine monophosphate (cGMP).  cGMP activates 
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protein kinase G, which in turn leads to VSMC relaxation through mechanisms that involve a 
reduction in cytosolic [Ca2+] (43).  
Activation of protein kinase G also results in the phosphorylation of a number of proteins 
that are involved in the inhibition of smooth muscle cell proliferation, expression of adhesion 
molecules, and platelet aggregation (51).  Thus, in addition to its vasodilatory properties, NO has 
anti-thrombogenic effects.  As a result, reductions in the bioavailability of endothelium-derived 
NO can cause a shift toward a pro-thrombotic and vasoconstrictive state, which contributes to the 
development of atherosclerotic vascular disease (44).   
 
Endothelial Vasomotor Function: Role of Endothelin-1 
The vascular endothelium is also capable of releasing vasoconstrictor substances.  The 
primary vasoconstrictor peptides produced by the endothelium are the endothelins (ETs).  The 
ET family consists of four 21-amino-acid peptides: ET-1, ET-2, ET-3, and ET-4 (52,53).  Of 
these peptides, ET-1 is the major vascular isoform and of most importance in the cardiovascular 
system (54).  Large pre-proendothelin peptides are cleaved by endopeptidases to form big ET-1, 
which is converted to ET-1 by ET-converting enzymes (ECE) (55).  Factors that modulate 
expression of ET-1 include shear stress, angiotensin II, thrombin, hypoxia, and inflammatory 
cytokines such as tumor necrosis factor (TNF)-α and interleukin (IL)-2 (55).  The majority of 
ET-1 produced by the endothelium (>80%) is released abluminally toward the vascular smooth 
muscle (56). 
The vascular actions of ET-1 are mediated by two distinct receptor subtypes.  ETA and 
ETB receptors located on the vascular smooth muscle mediate the vasoconstrictor effects of ET-
1.  Binding of ET-1 to these receptors activates the phospholipase C-inositol triphosphate 
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pathway, which results in an increase in intracellular [Ca2+], leading to phosphorylation of 
myosin kinase and subsequent smooth muscle cell contraction (52,57).  ETB receptors are also 
found on ECs, where their activation results in vasodilation mediated primarily by NO (58).  
Thus, activation of ETB receptors can lead to dual vasoregulatory actions.   
ET-1 system activation has been implicated in the initiation and progression of 
atherosclerotic vascular disease (59).  Increased expression of ET-1 and ECE has been observed 
in human arteries at different stages of atherosclerosis (60,61), and elevated levels of ET-1 have 
been found in human atherosclerotic lesions (60,62,63).  There are several potential mechanisms 
by which ET-1 may contribute to atherogenesis.  ET-1 stimulates platelet aggregation, cell 
adhesion molecule expression, and smooth muscle cell proliferation, all of which are 
characteristic features of atherosclerotic lesion development (64,65). ET-1 is also involved in the 
inflammatory component of atherosclerosis via activation of the transcription factor NF-κB, 
which stimulates the production of proinflammatory cytokines and activates leukocyte 
chemotaxis (64).  As a result, ET-1 system activation is involved in both vasomotor regulation 
and atherosclerotic disease progression.   
 
Endothelial Fibrinolytic Regulation 
 In addition to the control of vasomotor tone, the endothelium regulates the endogenous 
fibrinolytic system.  The fibrinolytic system serves as a counterbalance against coagulation and 
protects against thrombus formation by regulating fibrin deposition on the surface of the 
endothelium (49).  The modulation and resolution of thrombi associated with unstable 
atherosclerotic plaques are dependent on the effectiveness of the fibrinolytic system (49).  
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Dysfunction of endothelial fibrinolytic regulation leads to a prothrombotic state and an increased 
risk of atherothrombotic vascular disease (49).   
The vascular endothelium regulates fibrinolysis through the synthesis and release of 
activators and inhibitors, including the pro-enzyme plasminogen, tissue-type plasminogen 
activator (t-PA), plasminogen activator inhibitor (PAI)-1, and plasmin (49).  Following the 
initiation of thrombus formation, the endothelium acutely releases t-PA in response to several 
factors related to the coagulation cascade, including thrombin and factor Xa (66).  Upon its 
release, t-PA binds to thrombus-bound plasminogen and catalyzes its conversion to plasmin, 
which facilitates thrombus dissolution through the proteolytic degradation of fibrin to soluble 
fibrin degradation products (49).  Synthesis and release of t-PA is a critical aspect of endothelial 
function, as it is the primary activator of the fibrinolytic system.   
The endothelium is the principal site of t-PA generation (49).  Endothelial cells 
synthesize and constitutively secrete t-PA in vitro (67).  This continuous release contributes to 
the ~5 ng/mL concentration of t-PA antigen that is typically found in human plasma (49).  
However, only a small amount is active due to the presence of serine protease inhibitors, 
particularly PAI-1.  The interaction of PAI-1 and t-PA occurs rapidly and PAI-1 concentrations 
are several-fold higher than t-PA concentrations in plasma, yielding a large amount of plasma t-
PA inactive (68,69).  Upon stimulation, however, the endothelium is capable of substantially 
increasing t-PA release.  The precise signaling pathway has yet to be elucidated, but evidence 
suggests that the primary factor responsible for the acute release of t-PA from intracellular 
storage vesicles is a large increase in cytosolic [Ca2+] (70,71).  Acute release of t-PA is crucial to 
the effectiveness of the fibrinolytic system as it allows active unbound t-PA to reach the surface 
of a developing thrombus (49).  Indeed, fibrinolysis is much more effective if t-PA is 
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incorporated during, as opposed to after, thrombus formation (72).  As a result, the capacity of 
the vascular endothelium to rapidly release t-PA represents a vital component of the endogenous 
fibrinolytic system (73).   
Summary 
The vascular endothelium serves several functions that maintain vascular homeostasis 
and preservation of endothelial function is a key component of cardiovascular health.  
Endothelial dysfunction, including dysregulation of vasomotor and fibrinolytic function, 
represents a key mechanism contributing to the development of atherosclerotic vascular disease 
in at-risk populations.   
Hypertension and Vascular Endothelial Dysfunction 
Because of the significant cardiovascular risks associated with elevated BP, vascular 
endothelial function has been a target of extensive study in hypertensive patients.  These 
investigations indicate that hypertension is associated with endothelial dysfunction in the 
peripheral, coronary, and renal circulation (20-22). Endothelial dysfunction has been suggested 
to represent an important mechanism by which hypertension promotes the development and 
progression of CVD (19).  In fact, Perticone et al. observed that impaired endothelium-dependent 
vasodilation in the forearm was significantly associated with the development of clinical 
cardiovascular events after a mean follow-up period of ~32 months in a group of patients with 
essential hypertension (74). 
Hypertension and Endothelial Vasomotor Function: Nitric Oxide 
Early studies showing impaired endothelium-dependent vasodilation in animal models of 
hypertension provided the rationale for further research examining the role of endothelial 
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dysfunction in hypertensive humans (75-77).  Two studies that were published in 1990 provided 
the first evidence of endothelial dysfunction in patients with essential hypertension in vivo 
(22,78).  Panza and colleagues studied the forearm blood flow response to intra-arterial infusions 
of acetylcholine, an endothelium-dependent vasodilator, and sodium nitroprusside, an 
endothelium-independent vasodilator, in 18 hypertensive patients and 18 non-hypertensive 
control subjects (22).  The forearm blood flow response to acetylcholine was significantly lower 
in the hypertensive subjects compared with control subjects, while no significant differences in 
the response to sodium nitroprusside were observed between groups, indicating that 
endothelium-dependent vasodilation is impaired in patients with essential hypertension, without 
any loss of vascular smooth muscle function (22).  These findings have been replicated in several 
subsequent studies in the human forearm circulation, reinforcing the idea that hypertension is 
associated with impaired endothelium-dependent vasodilation (79-84).  Importantly, this 
dysfunction in endothelium-dependent vasodilation extends to the coronary vascular bed in 
patients with essential hypertension (20,85).   
 Due to the importance of NO in maintaining normal endothelial function, the effects of 
hypertension on NO bioavailability have been studied.  Calver and colleagues infused the eNOS 
inhibitor NG-monomethyl-L-arginine (L-NMMA) intra-arterially to study basal NO activity in 
hypertensive patients and non-hypertensive controls (86).  Patients with essential hypertension 
had a significantly blunted vasoconstriction response to L-NMMA compared with control 
subjects, indicating reduced NO availability with hypertension (86).  Furthermore, urinary 
excretion of 15N nitrate, the metabolic oxidation product of NO, following administration of 15N-
labelled arginine was reduced in hypertensive patients compared with non-hypertensive controls, 
indicating that whole body NO production is diminished under basal conditions (87).  While the 
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authors of these studies concluded that hypertension results in impaired NO bioavailability and 
subsequent endothelial dysfunction, it has also been postulated that reductions in basal NO 
production may contribute to the development of high BP.  This idea is supported by results from 
Gamboa et al., who used systemic L-NMMA infusion during complete autonomic blockade to 
show that endothelial-derived NO tonically restrains BP by approximately 30 mm Hg in humans 
(88).  Thus, in addition to being a consequence of hypertension, a loss of NO bioavailability may 
also be a potential cause of elevated BP.   
Hypertension and Endothelial Vasomotor Function: Endothelin-1 
 In an attempt to gain further understanding of the pathophysiology of endothelial 
vasomotor dysfunction associated with hypertension, Cardillo and colleagues performed a series 
of investigations examining the role of ET-1 in regulating vasomotor tone in patients with 
essential hypertension (89,90).  First, FBF responses to intra-arterial infusion of an ETA receptor 
antagonist (BQ-123) and an ETB receptor antagonist (BQ-788) were measured in hypertensive 
patients and normotensive control subjects (90).  In control subjects, BQ-123 alone or in 
combination with BQ-788, had no effect on FBF. In hypertensive patients, infusion of BQ-123 
alone led to a significant (~35%) increase in FBF, indicating that ETA-mediated vasoconstriction 
is enhanced in these subjects.  In addition, the combination of BQ-123 and BQ-788 resulted in an 
even greater increase in FBF (~65%) in subjects with hypertension.  Moreover, while infusion of 
BQ-788 alone caused vasoconstriction in normotensive subjects, it caused vasodilation in 
subjects with hypertension.  Collectively, these results indicate that hypertension is associated 
with increased vascular ET-1 activity and dysfunctional ETB-mediated vasodilation, which may 
contribute to the increased vascular tone observed in this population (90). 
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In a subsequent investigation, the FBF response to intra-arterial infusion of acetylcholine 
was measured in hypertensive patients and non-hypertensive control subjects before and after 
non-selective blockade of ETA and ETB receptors (89).  In accordance with previous studies 
(22,91), the vasodilator response to acetylcholine was blunted in hypertensive patients compared 
with non-hypertensive controls.  Furthermore, non-selective blockade of ET receptors resulted in 
a significant increase in the FBF response to acetylcholine in hypertensives, while no change was 
observed in control subjects (89).  These findings indicate that the increased ET-1 activity 
observed in hypertensive patients contributes to the impaired endothelium-dependent vasodilator 
response that is observed in this population. 
In addition to influencing endothelial vasomotor function, enhanced ET-1 system activity 
is thought to contribute to the etiology of CVD in hypertension through additional mechanisms, 
including the promotion of inflammation and oxidative stress, as well as vascular smooth muscle 
cell hypertrophy (55).  In a genetically engineered mouse with endothelium-restricted over-
expression of ET-1, increased ET-1 production was associated with enhanced activity of 
NADPH oxidase, as well as structural remodeling and endothelial dysfunction of resistance 
vessels (92).  ET-1-mediated hypertrophic remodeling of resistance arteries has also been 
demonstrated in salt-dependent models of experimental hypertension (93,94).   
Clinical trials examining the effects of ET receptor antagonists as potential anti-
hypertensive medications have provided evidence that ET-1 is also involved in the pathogenesis 
of hypertension.  Daily administration of the combined ETA/ETB antagonist bosentan (500 to 
2000 mg/day) lowered diastolic BP by ~6 mm Hg following 4 weeks of treatment in patients 
with mild-to-moderate hypertension (diastolic BP 95 – 115 mm Hg), a reduction that was 
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comparable to the effects of the angiotensin converting enzyme (ACE) inhibitor enalapril (95).  
Also, 6 weeks of treatment with the selective ETA receptor antagonist darusentan (100 mg/day) 
reduced systolic BP by 11.3 mm Hg in hypertensive patients (96).  Although negative side 
effects and inconvenient dosing patterns of ET receptor antagonists have limited enthusiasm for 
their use as anti-hypertensive medication (97), the BP-lowering effects shown in these studies 
provide convincing evidence that ET-1 is involved in the pathophysiology of high BP.   
Hypertension and Endothelial Fibrinolytic Regulation 
 The high prevalence of thrombotic complications associated with hypertension has 
directed research towards examination of thrombogenic abnormalities that may be linked to 
elevations in BP, including alterations in fibrinolytic function.  The first indication that 
hypertension may be associated with an altered fibrinolytic balance came with the observation of 
a significant correlation between plasma PAI-1 levels and systolic BP in a group of healthy 
middle-aged men and women (98).  Hrafnkelsdottir and colleagues were the first to examine 
stimulated endothelial t-PA release in the forearm vasculature of hypertensive humans (99).  In 
response to intra-arterial infusions of desmopressin, an established stimulator of endothelial t-PA 
release, hypertensive patients released a significantly lower amount of t-PA than non-
hypertensive control subjects (99).  Importantly, endothelium-independent vasodilation by 
sodium nitroprusside had no stimulatory effect on t-PA release, indicating that this difference in 
t-PA release was not due to differences in FBF between the two groups. These investigators later 
replicated this finding in a group of hypertensive patients with chronic kidney disease (100).  
Collectively, these results provided the first in vivo evidence that patients with essential 
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hypertension have an impaired capacity for stimulated t-PA release from the vascular 
endothelium. 
Hypertensive patients also display impaired t-PA release in response to acetylcholine 
(101,102) and adrenergic stimulation with epinephrine (103). It has been suggested that the 
blunted capacity for endothelial t-PA release associated with hypertension is linked to the 
decrease in NO bioavailability that characterizes this condition, and that patients with essential 
hypertension depend exclusively on t-PA release via an endothelium-derived hyperpolarizing 
factor-dependent pathway (102).  However, the suggested role of NO in modulating t-PA release 
is debatable, as other laboratories have shown t-PA release to either increase (104) or not change 
(105) during eNOS blockade in the forearm vasculature of healthy subjects. 
In vitro investigation has provided insight into the mechanisms by which hypertension is 
associated with impaired stimulated t-PA release (106).  Using a computerized vascular 
perfusion model to regulate intraluminal pressure in human umbilical vein segments, six hours of 
elevated pressure led to downregulation of t-PA gene and protein expression, as well as reduced 
vascular t-PA secretion (106).  These findings indicate that the impaired capacity for stimulated 
t-PA release in hypertensive patients may be an effect of elevated intraluminal pressure per se.  
Support for this concept has been established in vivo with the observation of an improved 
capacity for acute t-PA release in hypertensive patients following 8 weeks of BP-lowering 
therapy (107).  Anti-hypertensive treatment with either an ACE inhibitor or a calcium channel 
blocker augmented stimulated t-PA release, suggesting that the improvement in t-PA release is 
not drug-class dependent and that BP reduction alone enhances endothelial fibrinolytic function.   
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Summary 
 There is convincing evidence that essential hypertension is associated with abnormal 
endothelial vasomotor and fibrinolytic function.  Specifically, hypertension is associated with 
impaired endothelium-dependent vasodilation due in part to reduced NO bioavailability and 
enhanced ET-1 system activation, as well as an impaired capacity for stimulated endothelial t-PA 
release.  Importantly, endothelial dysfunction contributes to the increased risk of CVD in patients 
with essential hypertension (74). 
Prehypertension and Endothelial Function   
Limited information is currently available regarding the influence of prehypertension on 
endothelial function.  An early study comparing individuals with “borderline hypertension” 
(defined as BP = 130-140/85-90 mm Hg) to subjects with BP < 130/85 mm Hg found no 
difference in flow-mediated dilation (FMD) between groups (40).  However, the inclusion of 
prehypertensive individuals in the “control” group may have confounded the results of that 
study.  In contrast to these findings, subjects with high-normal BP (130-139/85-89 mm Hg) had a 
~30% lower FMD response than subjects with BP below 120/80 mm Hg (108).  Moreover, when 
the high-normal BP group was stratified by systolic BP, subjects with systolic BP between 135 
and 140 mm Hg had a significantly lower FMD than subjects with a systolic BP between 125 
and 135 mm Hg (108).  These results indicate that impairments in conduit artery endothelial 
function are apparent at BP levels in the prehypertensive range.  Finally, coronary flow reserve is 
impaired in prehypertensive subjects compared with normotensive subjects, indicating that 
prehypertension is associated with impaired coronary microvascular function (109).  However, 
the function of the endothelium was not directly examined in this investigation.   
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The capacity for stimulated endothelial t-PA release has been studied in young subjects 
with “borderline hypertension” (defined as SBP 140-160 mm Hg or DBP 85-95 mm Hg) (110).  
Methacholine was administered intra-arterially to ten young men with borderline hypertension 
and ten normotensive controls.  Net t-PA release in response to methacholine was not different 
between groups.  However, the individuals included in this study were not classified using JNC 
VII guidelines and all subjects were healthy men between the ages of 22 and 27 years.  As a 
result, the findings of this study may not be representative of the population of prehypertensive 
individuals in whom an elevated CVD risk has been observed.    
Summary  
 Although little is known regarding the influence of prehypertension on vascular 
endothelial function, there is evidence to suggest that impairments in vascular function may 
occur prior to the development of hypertension.  Future studies are necessary to determine if 
specific aspects of vascular endothelial function, including vasomotor control and fibrinolytic 
regulation, are impaired in individuals with prehypertension. 
Future Research Directions 
 While there is substantial evidence to support the idea that prehypertension is associated 
with an increased risk of CVD, the mechanisms responsible for this heightened cardiovascular 
risk are not completely understood.  Specifically, very little information is available regarding 
the impact of prehypertension on endothelial function.  Considering the established role of 
endothelial dysfunction in the development of CVD associated with hypertension, as well as 
evidence of an elevated cardiovascular risk in individuals with prehypertension, it is possible that 
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abnormalities in endothelial function associated with elevated BP may actually develop during 
the prehypertensive state.  Moreover, many of the investigations that have studied endothelial 
function in hypertensive populations have used a control group that includes subjects with BP in 
the prehypertensive range.  Therefore, the endothelial phenotype associated with prehypertension 
has not been accurately characterized.  If endothelial dysfunction is occurring earlier in the 
development of elevated BP, specifically during the prehypertensive state, this would provide a 
therapeutic target for the prevention of atherosclerotic vascular disease that is associated with 
elevated BP and emphasize the importance of alerting the public to the health risks associated 
with BP in the prehypertensive range.   
Investigations designed to determine whether endothelial vasomotor and/or fibrinolytic 
function are impaired in prehypertensive adult humans will provide insight to advance our 
understanding of the increased cardiovascular risk in this population. Furthermore, if 
impairments in vasomotor and/or fibrinolytic function are indeed found in prehypertensive 
adults, it would be important to determine the mechanisms by which BP in the prehypertensive 
range causes endothelial dysfunction.  These experiments will help elucidate the role that 
endothelial dysfunction may play in the increased cardiovascular risk associated with 
prehypertension and provide the experimental rationale for future studies aimed at improving 
endothelial function and, in turn, reducing the risk of CVD in prehypertensive adults.    
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ABSTRACT 
Background: Endothelial vasodilator dysfunction contributes to the development of 
hypertension (blood pressure (BP) ≥ 140/90 mm Hg) and cardiovascular disease (CVD).  
Prehypertension (BP 120-139/80-89 mm Hg) has recently been identified as an independent risk 
factor for hypertension and CVD. It is currently unclear whether BP in the prehypertensive range 
is associated with endothelial vasodilator dysfunction. We tested the hypothesis that blood 
pressure in the prehypertensive range, independent of other cardiovascular risk factors, is 
associated with impaired NO-mediated endothelium-dependent vasodilation.  Methods: Forearm 
blood flow (FBF) responses to intra-arterial acetylcholine (ACh; 8.0-32.0 µg/100 mL tissue/min) 
and sodium nitroprusside (SNP; 1.0-4.0 µg/100 mL tissue/min) were measured in 20 
normotensive (age: 56±1 yrs; BP: 110/70±1/2 mm Hg) and 20 prehypertensive (56±2 yrs; 
128/79±2/2 mm Hg) adults. In addition, FBF responses to ACh were determined in the absence 
and presence of the endothelial NO synthase inhibitor L-NMMA (5mg/min). Results: FBF 
responses to ACh were significantly lower (~30%) in prehypertensive (from 4.2 ± 0.3 to 11.4 ± 
0.7 mL/100 mL tissue/min) compared with normotensive (from 4.6 ± 0.2 to 14.5 ± 0.7 mL/100 
mL tissue/min) adults. There were no group differences in FBF responses to SNP.  Co-infusion 
of L-NMMA significantly reduced the FBF response to ACh in the normotensive (~30%; 
P<0.05) but not the prehypertensive adults.  Conclusions: Prehypertension is associated with 
impaired NO-mediated endothelium-dependent vasodilation. The endothelial vasodilator 
dysfunction that characterizes hypertension is present at BP levels in the prehypertensive range 
and may contribute to the increased risk of hypertension and CVD in this population.
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INTRODUCTION 
Several epidemiological studies have demonstrated a continuous positive relation 
between blood pressure (BP) and cardiovascular disease (CVD) risk that begins at BP levels 
well-below the traditional threshold for clinical hypertension (systolic BP ≥140 and/or diastolic 
BP ≥ 90 mm Hg)(1-3).  As a reflection of the linear relation between elevated BP and CVD risk, 
the guidelines set forth by the most recent report from the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of Hypertension (JNC-7) included a new 
category termed “prehypertension” to describe individuals with systolic BP 120-139 and/or 
diastolic BP 80-89 mm Hg (4).  Although the inclusion of this category was not intended to 
introduce a new disease category, several subsequent studies have indicated that prehypertension 
is an independent risk factor for the development of clinical hypertension, as well as coronary 
artery disease and its clinical consequences such as myocardial infarction and stroke (2,5-7).  
Moreover, ~50% of BP-related deaths occur in individuals with systolic BP between 115 and 
140 mm Hg, suggesting that prehypertension accounts for a significant proportion of CVD-
related mortality attributed to high BP (8).  
Dysfunction of the vascular endothelium, especially impaired endothelium-dependent 
vasodilation, is etiologically involved in the pathogenesis of atherosclerotic vascular disease and 
occurs early in atherogenesis, prior to histological or angiographic evidence of disease (9,10).  
Impairments in endothelium-dependent vasodilation are largely mediated by a reduction in the 
bioavailability of endothelium-derived nitric oxide (NO) (11).  Diminished NO-mediated 
endothelium-dependent vasodilation has been linked to an increased risk of future coronary 
artery disease, cerebrovascular disease, and atherothrombotic events (12,13).  In addition, 
clinical hypertension is associated with impaired NO-mediated endothelium-dependent 
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vasodilation (14-16).  Given the elevated CVD risk associated with prehypertension, it is 
possible that impairments in NO-mediated endothelium-dependent vasodilation arise at BP levels 
in the prehypertensive range.  If so, this may be an important underlying mechanism contributing 
to the development of clinical hypertension and atherosclerotic vascular disease in this 
population.   
Accordingly, we tested the hypothesis that blood pressure in the prehypertensive range is 
associated with impaired NO-mediated endothelium-dependent vasodilation.  To address this 
hypothesis, we measured forearm blood flow responses to intra-arterial infusion of acetylcholine, 
in the absence and presence of the endothelial NO synthase inhibitor L-NMMA, in normotensive 
and prehypertensive adults. 
 
METHODS 
Subjects 
Forty adults were stratified based on BP according to JNC-7 guidelines (4): 20 
normotensive [BP < 120/80 mmHg; 12 males/8 females] and 20 prehypertensive (BP 120-
139/80-89 mmHg; 11 males/9 females).  All subjects were non-obese and free of overt 
cardiovascular, metabolic, and chronic inflammatory disease as assessed by medical history, 
physical examination, and fasting blood chemistries. All subjects were free of recent 
infection/inflammation (<2 weeks), as determined by questionnaire (17).  Men over the age of 40 
years and women over the age of 50 years were further evaluated for clinical evidence of 
coronary artery disease with electrocardiograms and BP at rest and during incremental exercise 
performed to exhaustion.  All of the women were at least 1 year postmenopausal and had never 
taken or had discontinued use of hormone replacement therapy at least 1 year before the start of 
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the study. None of the subjects smoked, were taking medications, or performed regular physical 
exercise for at least 6 months before the start of the study. Daily physical activity was assessed 
by the Stanford Physical Activity Questionnaire and used to document the sedentary status (i.e., 
absence of regular aerobic and other types of exercise) of all subjects (18,19).  Family history of 
hypertension was assessed by questionnaire.  Before participation, all of the subjects had the 
research study and its potential risks and benefits explained fully before providing written 
informed consent according to the guidelines of the University of Colorado at Boulder. 
 
Blood Pressure Measurement 
BP measurement was completed in strict accordance with American Heart Association 
guidelines as established by the Council for High Blood Pressure Research (20).  Resting BP 
measurements were performed in the sitting position between 8 a.m. and 10 a.m. on at least two 
separate days one week apart.  Caffeinated beverages were avoided for at least 30 minutes prior 
to measurement.  The recordings were made under quiet, comfortable ambient (~24°C) 
laboratory conditions.  To avoid any possibility of investigator bias, measurements were made 
with a semi-automated device (Dinamap, Critikon, FL) that uses an oscillometric technique over 
the brachial artery. An appropriately sized cuff (cuff bladder encircling at least 80 percent of the 
arm) was used.  Recordings were made in triplicate in the upright sitting position and the average 
recorded. 
 
Body Composition and Metabolic Measurements 
Body mass was measured to the nearest 0.1 kg using a medical beam balance.  Percent 
body fat was determined by dual energy X-ray absorptiometry (Lunar Corp., Madison, WI).  
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Body mass index (BMI) was calculated as weight (kilograms) divided by height (meters) 
squared.  Minimal waist circumference was measured according to published guidelines (21).  
Fasting plasma lipid, lipoprotein, glucose, and insulin concentrations were determined using 
standard techniques as previously described (22).  The presence of the metabolic syndrome was 
established according to the National Cholesterol Education Program ATP III criteria (23,24).   
 
Maximal Oxygen Consumption (VO2 max) 
 To assess aerobic fitness, subjects performed incremental treadmill exercise with a 
modified Balke protocol.  Maximal oxygen consumption (VO2 max) was measured with on-line 
computer-assisted open circuit spirometry as described previously (25). 
 
Intra-Arterial Infusion Protocol 
All studies were performed between 7 am and 10 am in a temperature-controlled room 
following a 12-hour overnight fast as previously described (22).  Under local anesthesia (1% 
lidocaine), a 5-cm, 20-gauge catheter was inserted in the brachial artery of the non-dominant 
arm.  Forearm blood flow (FBF) was measured in both the experimental (non-dominant) and 
contralateral (dominant) forearm using strain-gauge venous occlusion plethysmography.  FBF 
was measured at baseline and in response to acetylcholine (ACh; IOLAB Pharmaceuticals) 
infused intra-arterially at 4.0, 8.0, 16.0 µg/100 mL tissue/min and sodium nitroprusside (SNP; 
Abbott Laboratories) at 1.0, 2.0 and 4.0 µg/100 mL tissue/min for 3 to 5 minutes at each dose. 
The sequence of drug administration was randomized to avoid an order effect. 
To determine the contribution of NO to ACh-mediated vasodilation, FBF responses to 
ACh were determined before and after administration of the endothelial NO synthase (eNOS) 
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inhibitor NG-monomethyl-L-arginine (L-NMMA; Clinalfa) in 16 of the 20 normotensive (9 
males/7 females) and 16 of the 20 prehypertensive (10 males/6 females) adults.  After ACh was 
infused at the doses noted above and FBF was allowed to return to resting levels, L-NMMA was 
infused at 5 mg/min for 5 min.  Immediately thereafter, the ACh dose response was repeated 
with the continuous infusion of L-NMMA. 
 
Statistical Analysis 
Differences in subject characteristics and area under the curve data were determined by 
analysis of variance (ANOVA).  Group differences in FBF responses to ACh, SNP, and ACh+L-
NMMA were determined by repeated measures ANOVA.  When indicated by a significant F 
value, a post hoc test using the Newman-Keuls method was performed to identify differences 
among the groups.  Pearson correlations were determined between variables of interest.  There 
were no significant sex differences with respect to the main effect of BP on any of the key 
outcome variables; therefore, the data were pooled and are presented together.  Power 
calculations were performed a priori to determine the appropriate number of subjects per group.  
All data are presented as mean ± SEM.  Statistical significance was set at P<0.05. 
 
RESULTS 
 Selected subject characteristics are presented in Table 1.  Anthropometric characteristics 
were similar between groups.  By design, both systolic and diastolic BP were significantly higher 
(p<0.05) in the prehypertensive group compared with the normotensive controls.  There were no 
differences between the groups in maximal oxygen consumption or plasma lipid and lipoprotein, 
glucose, and insulin concentrations.  Four subjects in the prehypertensive group met the criteria 
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for the metabolic syndrome, and eight subjects (5 prehypertensive; 3 normotensive) reported a 
family history of hypertension. 
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Table 1: Selected subject characteristics. 
Variable Normotensive (n=20) 
Prehypertensive 
(n=20) 
BMI = body mass index; BP = blood pressure; VO2 max = maximal oxygen consumption; 
HDL = high-density lipoprotein; LDL = low-density lipoprotein 
Values are means ± SEM 
*P<0.05 vs. normotensive 
 
Males/Females 12/8 11/9 
Age (yrs) 56 ± 1 56 ± 2 
Body mass (kg) 77.5 ± 2.4 79.5 ± 2.7 
BMI (kg/m2) 26.4 ± 0.7 27.1 ± 0.5 
Body fat (%) 31.5 ± 2.2 34.4 ± 2.0 
Waist circumference (cm) 88.3 ± 1.8 90.8 ± 2.4 
Waist-to-hip ratio 0.87 ± 0.02 0.88 ± 0.02 
VO2 max (L/min) 2.5 ± 0.2 2.4 ± 0.2 
Systolic BP (mmHg) 110 ± 1 128 ± 2* 
Diastolic BP (mmHg) 70 ± 2 79 ± 2* 
Total Cholesterol (mmol/L) 5.1 ± 0.2 5.3 ± 0.2 
HDL-Cholesterol (mmol/L) 1.4 ± 0.1 1.3 ± 0.1 
LDL-Cholesterol (mmol/L) 3.2 ± 0.1 3.3 ± 0.2 
Triglycerides (mmol/L) 1.1 ± 0.2 1.4 ± 0.2 
Glucose (mmol/L) 5.0 ± 0.1 5.3 ± 0.1 
Insulin (pmol/L) 29.4 ± 2.6 34.1 ± 3.9 
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 Resting FBF was not different between the normotensive (4.6 ± 0.2 mL/100 mL 
tissue/min) and prehypertensive (4.2 ± 0.3 mL/100 mL tissue/min) subjects.  The vasodilator 
response to ACh was markedly blunted (~25%; P<0.05) in the prehypertensive (from 4.2 ± 0.3 to 
11.4 ± 0.7 mL/100 mL tissue/min) compared with normotensive (from 4.6 ± 0.2 to 14.5 ± 0.7 
mL/100 mL tissue/min) adults (Figure 1).  As a result, total FBF to ACh (area under the curve) 
was significantly lower in the prehypertensive (53.3 ± 5.6 mL/min) than normotensive group 
(71.9 ± 5.9 mL/min).  FBF responses to SNP were not significantly different between the groups 
(Figure 1).  Heart rate, mean arterial BP and FBF in the non-infused arm, remained constant 
throughout the infusion protocol in both the prehypertensive and normotensive adults (data not 
shown).  Systolic BP (r = -0.31; P < 0.05) was the only correlate of the FBF response to ACh in 
the overall study population.  Group differences in FBF responses to ACh were maintained when 
subjects with the metabolic syndrome or a family history of hypertension were excluded from 
analysis.  
 Co-infusion of L-NMMA significantly reduced the FBF responses to ACh in the 
normotensive but not the prehypertensive adults (Figure 2).  For example, in the normotensive 
group, FBF at the highest dose of ACh declined from 14.3 ± 0.8 mL/100 mL tissue/min to 10.6 ± 
0.9 mL/100 mL tissue/min with L-NMMA.  In contrast, FBF at the highest dose of ACh in the 
prehypertensive group was largely unaffected by L-NMMA (from 10.8 ± 1.0 mL/100 mL 
tissue/min to 9.0 ± 1.2 mL/100 mL tissue/min).  Consequently, total FBF to ACh was ~30% 
lower (P < 0.05) in the presence of L-NMMA in the normotensive adults compared with a 
modest ~15% reduction (P = 0.43) in total FBF to ACh in the prehypertensive adults.
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Figure 1:  FBF responses (panel A) and total FBF (area under the curve) (panel B) to acetylcholine and sodium nitroprusside (panel 
C) in normotensive and prehypertensive adults.   
 
 
 
 
 
 
 
 
 
 
 
 
Values are means ± SEM. *P < 0.05 vs. normotensive.
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Figure 2:  FBF responses and total FBF (area under the curve) to acetylcholine in the absence 
and presence of the nitric oxide (NO) synthase inhibitor NG-monomethyl-L-arginine (L-NMMA) 
in normotensive and prehypertensive adults.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values are means ± SEM. *P < 0.05 vs. saline. 
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DISCUSSION 
 The seminal findings of the present study are as follows:  1) otherwise healthy adults with 
BP in the prehypertensive range exhibited impaired endothelium-dependent vasodilation 
compared with normotensive adults of similar age and body composition; and 2) the contribution 
of NO to endothelium-dependent vasodilation was significantly diminished in adults with 
prehypertension.  Taken together, these results indicate that prehypertension is associated with 
impaired NO-mediated endothelium-dependent vasodilation.  Diminished NO-mediated 
endothelial vasodilator function may contribute to the increased risk of hypertension and 
atherosclerotic vascular disease in this population. 
 Because of the significant cardiovascular risk associated with elevated BP and the well-
established role of the vascular endothelium in maintaining cardiovascular health, endothelial 
vasodilator function has been a target of extensive study in adults with hypertension (14-16,26).  
These studies have repeatedly demonstrated that BP in the clinical hypertensive range is 
associated with impaired endothelium-dependent vasodilation in several vascular beds, including 
the coronary, peripheral, and renal circulation (14-16).  Moreover, impaired acetylcholine-
mediated endothelium-dependent vasodilation predicts future cardiovascular events in 
hypertensive adults, underscoring the clinical importance of this aspect of endovascular health in 
individuals with hypertension (27).  In light of recent data demonstrating that prehypertension is 
an independent risk factor for CVD (2,5-7), it has been suggested that the cardiovascular 
consequences of hypertension may already be apparent in the prehypertensive state (26,28).  The 
results of the present study support this notion.  Indeed, FBF responses to acetylcholine were 
significantly blunted (~25%) in prehypertensive compared with normotensive adults.  
Furthermore, co-infusion of L-NNMA did not significantly alter FBF responses to acetylcholine 
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in the prehypertensive adults, indicating that a reduction in NO bioactivity contributes to 
impaired acetylcholine-mediated vasodilation with prehypertension.  Interestingly, the magnitude 
of impairment in the FBF response to acetylcholine in prehypertensive compared with 
normotensive adults in the present study was comparable to that observed in hypertensive adults 
reported in previous studies that utilized similar experimental procedures.  For example, Taddei 
et al. (29) reported that FBF responses to acetylcholine were ~25% lower in hypertensive (BP = 
154/100 mm Hg) compared with normotensive adults.  In addition, Panza et al. (30) have shown 
that co-infusion of L-NMMA does not significantly affect FBF responses to acetylcholine in 
hypertensive adults.  This finding is similar to that observed in prehypertensive adults in the 
present study.  Thus, our results indicate that the impairment in NO-mediated endothelium-
dependent vasodilation that characterizes hypertension is already present in the prehypertensive 
state. 
 Previous studies on the influence of BP in the prehypertensive range on endothelial 
vasodilator function have yielded conflicting results. An early study comparing individuals with 
“borderline hypertension” (defined as BP = 130-140/85-90 mm Hg) to those with BP < 130/85 
mm Hg reported no differences in flow-mediated dilation (FMD) between the groups (31).  
However, the inclusion of prehypertensive individuals in the “control” group may have 
confounded these results.  In contrast to these findings, Plavnik et al. (32) reported that adults 
with high-normal BP (130-139/85-89 mm Hg) demonstrated a ~30% lower FMD response than 
adults with BP below 120/80 mm Hg, suggesting that impairments in conduit artery endothelial 
function are apparent at BP levels in the prehypertensive range.  Although differences in BP 
stratification likely contributed to the discrepancy in results between these studies, the results of 
Plavnik et al. (32) are supported by data from Giannotti and colleagues (33) who demonstrated a 
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significantly lower FMD response in prehypertensive compared with normotensive adults.  The 
present study significantly extends these earlier findings by demonstrating impaired NO-
mediated endothelium-dependent vasodilation in prehypertensive adults free of other 
cardiometabolic risk factors who were strictly classified based on JNC-7 guidelines (4).    
 The mechanisms underlying impaired NO-mediated endothelium-dependent vasodilation 
with prehypertension are unclear.  A number of factors may play a role, however, including 
oxidative stress and inflammatory cytokines.  Prehypertension is associated with elevated levels 
of inflammatory markers such as C-reactive protein and tumor necrosis factor-α (34), as well as 
higher levels of oxidative stress markers such as oxidized LDL (35).  These inflammatory and 
oxidative factors can contribute to endothelial cell dysfunction.  For example, oxidized LDL 
impairs NO bioavailability by reducing eNOS activity directly, as well as promoting superoxide 
anion formation and the subsequent oxidative inactivation of NO (36,37).  Another possibility is 
that impairments in endothelium-dependent vasodilation with prehypertension are the result of 
enhanced endothelin (ET)-1 vasoconstrictor activity. ET-1 system activity is involved in the 
regulation of blood pressure and has been shown to be elevated in hypertensive adults (38-40).  It 
is currently unknown whether ET-1 vasoconstriction is enhanced with prehypertension.  If so, 
elevated ET-1 system activity might contribute to the impairment in NO-mediated endothelium-
dependent vasodilation in prehypertensive adults. 
 From a public health perspective, it is important to emphasize that we studied non-
medicated and non-smoking adults free of cardiometabolic abnormalities that are commonly 
associated with prehypertension (41) and known to influence endothelial function, such as 
obesity (22), dyslipidemia (42), and diabetes (43).  Although our cross-sectional study design 
does not allow conclusions regarding causality, the findings of the present study demonstrate that 
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BP in the prehypertensive range, independent of other cardiovascular risk factors, is associated 
with impaired NO-mediated endothelium-dependent vasodilation.  These results provide support 
for the emerging argument for earlier intervention in the treatment and prevention of high BP 
(28,44,45). Considering prehypertension is associated with accelerated progression of coronary 
atherosclerosis (46), carotid artery intima-media thickening (47,48) and endothelial dysfunction, 
interventions directed at lowering BP and reducing cardiovascular risk may need to be more 
strictly implemented at BP levels below the traditional clinical cut-off for hypertension. 
In conclusion, the results of the present study demonstrate that prehypertension is 
associated with impaired NO-mediated endothelium-dependent vasodilation. These data indicate 
that prehypertension is not a benign condition and provide further evidence that the endothelial 
vasodilator dysfunction that characterizes hypertension is apparent in the prehypertensive range.  
Impaired NO-mediated endothelium-dependent vasodilation may contribute to the increased risk 
of CVD in prehypertensive adults. 
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ABSTRACT 
Background: Prehypertension (blood pressure (BP): 120-139/80-89 mmHg) is an independent 
risk factor for hypertension and cardiovascular disease (CVD).  Currently, it is unknown whether 
ET-1-mediated vasoconstrictor tone is elevated with BP in the prehypertensive range. We 
determined whether endothelin (ET)-1 vasoconstrictor tone is elevated in prehypertensive adults 
and, if so, whether ET-1-mediated vasoconstriction contributes to endothelial vasodilator 
dysfunction in this population. Methods: Forearm blood flow (FBF) responses to selective ETA 
receptor blockade (BQ-123; 100 nmol/min) were determined in 26 normotensive (age: 55±1 yrs; 
BP: 112/72±1/1 mmHg) and 30 prehypertensive (57±1 yrs; 130/80±1/1 mmHg) adults. In a 
subset of subjects, FBF responses to non-selective ET-1 receptor blockade (BQ-123+BQ-788) 
were determined. FBF responses to acetylcholine (ACh; 8.0-32.0 µg/100 mL tissue/min) were 
measured in the absence and presence of selective ETA receptor blockade. Results: BQ-123 
elicited a significantly greater increase in FBF in prehypertensive (~20%) than normotensive 
(~5%) adults. Addition of BQ-788 resulted in a further increase (P<0.05) in FBF in 
prehypertensive but not normotensive adults. FBF responses to ACh were lower (P<0.05) in 
prehypertensive (4.6 ± 0.3 to 12.6 ± 0.5 mL/100 mL tissue/min) than normotensive (4.9 ± 0.3 to 
14.7 ± 0.8 mL/100 mL tissue/min) adults. Co-infusion of BQ-123 did not affect ACh-induced 
vasodilation in normotensive adults, but resulted in an ~20% increase (P<0.05) in 
prehypertensive adults.  Conclusions: ET-1-mediated vasoconstrictor tone is elevated with 
prehypertension, contributing to impaired endothelium-dependent vasodilation. ET-1 
vasoconstriction may underlie the increased risk of hypertension and CVD in prehypertensive 
adults.
  
62 
INTRODUCTION  
Prehypertension, defined as systolic blood pressure between 120-139 mm Hg and/or 
diastolic blood pressure between 80-89 mm Hg, is a common condition that affects ~30% of the 
US adult population (1,2).  A growing body of evidence indicates that prehypertension is not 
only an independent risk factor for the development of clinical hypertension (blood pressure ≥ 
140/90 mm Hg) (3,4), but also cardiovascular disease (CVD) and its clinical consequences, such 
as myocardial infarction, stroke, and congestive heart failure (1,5-7).  The increased 
cardiovascular risk associated with prehypertension may be mediated, at least in part, by vascular 
endothelial dysfunction.  Endothelial damage and dysfunction is considered to be a critical early 
event in the pathogenesis and progression of atherosclerotic vascular disease (8,9).  Recent data 
indicate that blood pressure in the prehypertensive range is associated with impaired nitric oxide 
(NO)-mediated endothelium-dependent vasodilation (10,11).  In addition to NO, endothelin 
(ET)-1 plays an important role in vascular health and vasomotor regulation (12,13). 
 ET-1 is the most potent vasoconstrictor released by the endothelium and has been linked 
to the etiology of hypertension (12,13).  Acute and chronic blockade of ET-1 receptors have been 
shown to reduce blood pressure and ameliorate endothelial vasodilator dysfunction in patients 
with clinical hypertension (14-17).  In addition to its vasoregulatory actions, ET-1 also promotes 
the development of atherosclerotic vascular disease by stimulating inflammatory cytokine 
release, platelet aggregation, cell adhesion molecule expression, and vascular smooth muscle cell 
proliferation (12,18,19).  Although elevations in ET-1 system activity have been demonstrated in 
patients with clinical hypertension (14,15), it is currently unknown whether increased ET-1 
vasoconstrictor tone is apparent at blood pressure levels in the prehypertensive range.  If so, 
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enhanced ET-1 system activity with prehypertension may contribute to elevations in blood 
pressure and the development of CVD in this population. 
 The aims of the present study were to determine whether ET-1 vasoconstrictor tone is 
elevated in prehypertensive adults and, if so, whether the increase in ET-1-mediated 
vasoconstriction contributes to endothelial vasodilator dysfunction in this population.  To address 
these aims, forearm blood flow responses to selective and non-selective ET-1 receptor 
antagonists were determined in normotensive and prehypertensive adults.  Additionally, 
acetylcholine-mediated endothelium-dependent vasodilation was assessed in the absence and 
presence of selective ET-1 receptor blockade.  We hypothesized that ET-1 vasoconstrictor tone is 
greater in prehypertensive compared with normotensive adults and that the elevation in ET-1-
mediated vasoconstriction contributes to impaired endothelium-dependent vasodilation with 
prehypertension. 
 
METHODS 
Subjects 
 Fifty-six middle-aged and older adults (age range: 42 – 65 years) were studied: 26 
normotensive (systolic blood pressure < 120 mmHg and diastolic blood pressure < 80 mmHg; 15 
males/11 females) and 30 prehypertensive (systolic blood pressure 120-139 mmHg and/or 
diastolic blood pressure 80-89 mmHg; 20 males/10 females). Blood pressure classification was 
based on guidelines from the Seventh Report of the Joint National Committee on Prevention, 
Detection, Evaluation and Treatment of High Blood Pressure (JNC 7) and established by two or 
more seated blood pressure readings from two separate laboratory visits over 10-14 days (20).  
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All subjects were sedentary and had not participated in a regular aerobic exercise program for at 
least 1 year prior to the start of the study. Subjects were excluded from the study if they 
presented a history or evidence of: hepatic, renal, or hematological disease; peripheral vascular 
disease; stroke; diabetes (fasting plasma glucose > 7.0 mmol/L) (21); dyslipoproteinemia (22); 
and hypertension (arterial blood pressure ≥ 140/90 mmHg) (20).  All subjects were screened for 
clinical evidence of cardiovascular disease by medical history, physical examination, fasting 
blood chemistries, and electrocardiograms and blood pressure at rest and during incremental 
exercise performed to exhaustion.  None of the subjects smoked or were taking medications 
including vitamins. All of the women were at least 1 year postmenopausal and had never taken 
or had discontinued use of hormone replacement therapy at least 1 year before the start of the 
study. Prior to participation, all of the subjects had the research study and its potential risks and 
benefits explained fully before providing written informed consent according to the guidelines of 
the University of Colorado at Boulder. 
Body Composition and Metabolic Measurements 
Body mass was measured to the nearest 0.1 kg using a medical beam balance (Detecto, Webb 
City, MO).  Percent body fat was determined by dual energy X-ray absorptiometry (Lunar 
Radiation Corporation, Madison, WI).  Body mass index (BMI) was calculated as weight 
(kilograms) divided by height (meters) squared.  Minimal waist circumference was measured 
according to published guidelines (23).  Fasting plasma lipid, lipoprotein, glucose, and insulin 
concentrations were determined using standard techniques as previously described (24).  
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Intra-arterial Infusion Protocol 
All studies were performed between 7:00 am and 10:00 am after a 12-hour overnight fast 
in a temperature-controlled room.  Under strict aseptic conditions a 5-cm, 20-gauge catheter was 
inserted into the brachial artery of the non-dominant arm under local anesthesia (1% lidocaine).  
Heart rate and arterial blood pressure were continuously measured throughout the infusion 
protocol.  Forearm blood flow (FBF) at rest and in response to each pharmacological agent was 
measured in both the experimental (non-dominant) and contralateral (dominant) forearm using 
strain-gauge venous occlusion plethysmography (D. E. Hokanson, Bellevue, WA), as previously 
described by our laboratory (25).  
Following measurement of baseline FBF (5 minutes), BQ-123 (Clinalfa, AG), a selective 
ETA receptor antagonist, was infused at a rate of 100 nmol/min for 60 minutes.  FBF was 
measured every 10 minutes throughout the infusion period.  The selected dose of BQ-123 has 
been shown to completely inhibit the vasoconstrictor effect of ET-1 in the human forearm of 
healthy adults (15,25).  After 60 minutes of BQ-123 infusion, the FBF response to non-selective 
ET-1 receptor blockade was assessed by the co-administration of BQ-123 and BQ-788 (Clinalfa, 
AG) for an additional 60 minutes.  FBF was measured every 10 minutes during the combined 
BQ-123 and BQ-788 infusion.  BQ-788, a specific antagonist of ETB receptors, was infused at a 
rate of 50 nmol/min, a dose shown to effectively inhibit ETB receptors (15,25).  Because of 
limited drug availability, studies involving BQ-788 were only performed in a subset of the total 
study population (16 prehypertensive and 10 normotensive adults). 
To assess the influence of ET-1 activity on endothelium-dependent vasodilation, FBF 
responses to acetylcholine (ACh) were measured in the absence and presence of BQ-123 in 12 of 
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the 26 normotensive (blood pressure: 110±2/70±2; 8 M/4 F) and 12 of the 30 prehypertensive 
(blood pressure: 129±2/80±2; 8 M/4 F) subjects.  Following the measurement of resting blood 
flow for 5 minutes, FBF was assessed in response to infusions of ACh (IOLAB pharmaceuticals, 
Duluth, GA) at 4.0, 8.0, and 16.0 µg/100 mL tissue/min and sodium nitroprusside (SNP; 
Nitropress, Abbott Laboratories) at 1.0, 2.0, and 4.0 µg/100 mL tissue/min.  Each dose of ACh 
and SNP was infused for ~5 minutes and sufficient time (~20 minutes) was allowed for FBF to 
return to resting levels between each vasoactive agent.  To avoid an order effect, the sequence of 
drug administration was randomized.  After the initial infusion of ACh and SNP, BQ-123 was 
infused in an identical manner to Study 1.  After 60 minutes, infusion of BQ-123 was continued 
at the same dose and FBF was reassessed during co-administration of ACh as performed earlier.   
Statistical Analysis 
 Differences in subject baseline characteristics were determined by between-groups 
analysis of variance (ANOVA).  Group differences in FBF responses to BQ-123, acetylcholine, 
and sodium nitroprusside were determined by repeated-measures ANOVA.  Pearson correlations 
were determined between variables of interest.  There were no significant gender interactions, 
therefore the data were pooled and presented together. All data are expressed as mean ± SEM. 
Statistical significance was set a priori at P <0.05.   
RESULTS 
 Selected subject characteristics are presented in table 1. There were no differences 
between the groups in anthropometric characteristics or plasma lipid and lipoprotein, glucose, 
and insulin concentrations.  By design, systolic blood pressure and diastolic blood pressure were 
greater (P<0.05) in the prehypertensive compared with the normotensive group.  FBF in the non-
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infused arm and mean arterial blood pressure remained constant throughout the infusion protocol 
and did not differ significantly between groups. 
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Table 2:  Selected Subject Characteristics. 
Variable Normotensive (n=26) 
Prehypertensive 
(n=30) 
BMI = body mass index; BP = blood pressure; HDL = high-density lipoprotein; LDL 
= low-density lipoprotein 
Values are mean ± SEM 
*P<0.05 vs. normotensive 
 
Males/Females 15/11 20/10 
Age (yrs) 55 ± 1 57 ± 1 
Body mass (kg) 77.0 ± 2.7 80.3 ± 2.5 
BMI (kg/m2) 25.8 ± 0.7 26.7 ± 0.6 
Body fat (%) 32.3 ± 2.1 32.0 ± 1.8 
Waist circumference (cm) 89.3 ± 2.7 91.6 ± 1.9 
Waist-to-hip ratio 0.88 ± 0.02 0.89 ± 0.02 
Systolic BP (mmHg) 112 ± 1 130 ± 1* 
Diastolic BP (mmHg) 72 ± 1 80 ± 1* 
Total Cholesterol (mmol/L) 5.0 ± 0.2 5.2 ± 0.1 
HDL-Cholesterol (mmol/L) 1.3 ± 0.1 1.3 ± 0.1 
LDL-Cholesterol (mmol/L) 3.2 ± 0.2 3.3 ± 0.1 
Triglycerides (mmol/L) 1.2 ± 0.1 1.2 ± 0.1 
Glucose (mmol/L) 5.1 ± 0.1 5.1 ± 0.1 
Insulin (pmol/L) 39.9 ± 4.1 39.1 ± 3.2 
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The FBF responses to selective ETA receptor blockade (BQ-123) were markedly different 
(P<0.05) between groups.  BQ-123 elicited a significantly greater increase in FBF in 
prehypertensive (~20%) than normotensive (~5%) adults (Figure 1).  FBF responses to BQ-123 
at the 60-minute time point were significantly related to systolic blood pressure (r=0.55), 
diastolic blood pressure (r=0.36), and mean arterial pressure (r=0.50).  The addition of BQ-788 
to BQ-123 did not significantly affect the FBF responses to BQ-123 in the normotensive adults.  
However, the prehypertensive adults demonstrated a further increase (~10%; P < 0.05) in FBF to 
BQ-123 + BQ-788 beyond that observed with BQ-123 alone (Figure 2).  As a result, significant 
group differences remained in the FBF responses to non-selective ETA/ETB blockade. 
FBF responses to ACh were ~20% lower (P<0.05) in the prehypertensive (from 4.6±0.2 
to 12.6±0.5 mL/100mL tissue/min) compared with the normotensive (from 5.0±0.2 to 14.7±0.8 
mL/100mL tissue/min) group.  There were no significant differences between the groups in FBF 
responses to SNP (Figure 3).  Co-infusion of BQ-123 with ACh did not significantly affect ACh-
mediated vasodilation in the normotensive subjects (Figure 4).  However, FBF to ACh increased 
(~30%; P < 0.05) in the prehypertensive adults with BQ-123 (Figure 4).  In fact, the co-infusion 
of BQ-123 abolished the blood pressure -related difference in ACh-mediated vasodilation 
between the groups.  FBF responses to ACh in the presence of BQ-123 were not significantly 
different between the normotensive (from 5.1±0.4 to 16.6±0.8 mL/100mL tissue/min) and 
prehypertensive (from 5.1±0.2 to 15.3±0.8 mL/100mL tissue/min) adults. 
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Figure 3:  Forearm blood flow (FBF) responses to BQ-123 (100 nmol/min) in normotensive and 
prehypertensive adults.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values are mean ± SEM.  *P<0.05 refers to the difference in FBF responses to BQ-123 in 
prehypertensive vs. normotensive adults. 
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Figure 4:  FBF responses to BQ-123 (100 nmol/min) alone and BQ-123 combined with BQ-788 
(50 nmol/min) in normotensive and prehypertensive adults.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values are mean ± SEM.  *P<0.05 refers to the difference in FBF responses to BQ-123 and BQ-
123+BQ-788 in prehypertensive vs. normotensive adults.  †P<0.05 refers to the difference in 
FBF responses to BQ-123 vs. BQ-123+BQ-788 among the prehypertensive adults. 
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Figure 5:  FBF responses to acetylcholine (panel A) and sodium nitroprusside (panel B) in 
normotensive and prehypertensive adults.  
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Figure 6: FBF responses to acetylcholine in the presence and absence of ETA receptor blockade with BQ-123 in normotensive (panel 
A) and prehypertensive (panel B) adults.  
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Values are mean ± SEM.  *P<0.05 vs. saline. 
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DISCUSSION 
 The novel findings of the present study are as follows: (1) selective ETA receptor 
blockade elicited a significantly greater vasodilator response in prehypertensive compared with 
normotensive adults; (2) non-selective ETA and ETB receptor blockade produced significantly 
greater vasodilation in prehypertensive adults than that produced by selective ETA antagonism; 
and (3) selective ETA receptor blockade increased ACh-mediated endothelium-dependent 
vasodilation in prehypertensive adults to levels similar to that of normotensive adults.  
Collectively, these findings indicate that ET-1-mediated vasoconstrictor tone is elevated with 
prehypertension independent of other CVD risk factors and contributes to the impairment in 
endothelium-dependent vasodilation in prehypertensive adults. 
 Although the introduction of the prehypertension blood pressure classification in the 
JNC-7 report was not initially intended to designate a new disease category (20), several studies 
have shown that prehypertension is an independent risk factor for clinical hypertension and 
adverse cardiovascular events, such as myocardial infarction and stroke (1,4-6).  These findings 
have led to the suggestion that the pathogenesis of blood pressure-related cardiovascular 
disorders begins at blood pressure levels in the prehypertensive range (26,27).  This notion is 
supported by recent data demonstrating that otherwise healthy adults with blood pressure in the 
prehypertensive range exhibit impaired endothelium-dependent vasodilation, similar to that 
observed in hypertensive adults (10,11).  The results of the present study significantly extend our 
understanding of the endothelial vasomotor dysfunction associated with prehypertension by 
demonstrating, for the first time, that prehypertensive adults exhibit elevated ET-1-mediated 
vasoconstrictor tone.   
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ET-1 vasoconstrictor activity is mediated by two distinct receptor subtypes, ETA and 
ETB.  ETA receptors are located exclusively on vascular smooth muscle cells, where ET-1 
binding activates the phospholipase C-inositol triphosphate pathway resulting in an increase in 
intracellular calcium, subsequent phosphorylation of myosin kinase and, in turn, long-lasting 
smooth muscle cell contraction (12,13). In contrast to ETA receptors, ETB receptors are 
expressed by both the endothelium and vascular smooth muscle and can mediate dual 
vasoregulatory actions of ET-1 (28).  Activation of ETB receptors expressed by the vascular 
smooth muscle elicits vasoconstriction, while ET-1 binding to ETB receptors on endothelial cells 
results in NO-mediated vasodilation (12,13).  The development of pharmacologic agents that 
selectively block the ETA and ETB receptors has provided a means of assessing the contribution 
of ET-1 to vasomotor regulation in vivo.  In the present study, prehypertensive adults exhibited a 
significantly greater vasodilator response to selective ETA receptor blockade than their 
normotensive counterparts, indicating that blood pressure in the prehypertensive range is 
associated with elevated ET-1 vasoconstriction mediated by the ETA receptor.  Furthermore, 
non-selective ETA/B receptor antagonism resulted in a further increase in FBF above that 
observed with ETA blockade alone in the prehypertensive adults only, demonstrating that the 
ETB receptor also contributes to the elevation in ET-1 vasoconstrictor tone with prehypertension.  
Thus, prehypertension is associated with enhanced ET-1 vasoconstrictor tone that is mediated by 
both the ETA and ETB receptor subtypes. 
Elevated ET-1 system activity in prehypertensive adults may have important 
pathophysiological implications.  Given ET-1’s potent vasoconstrictor actions, elevated ET-1-
mediated vasoconstriction may lead to increased vascular tone and further elevations in blood 
pressure in prehypertensive adults, thereby contributing to the elevated risk of progression to 
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clinical hypertension.  This idea is supported by the finding that chronic ET receptor blockade 
prevents blood pressure elevation in various animal models of hypertension (29-31).  In addition 
to inducing vasoconstriction, ET-1 receptor stimulation promotes fibrosis, vascular hypertrophy, 
inflammatory cytokine production, and smooth muscle cell proliferation, all of which contribute 
to atherogenesis (12,32,33).  In fact, chronic ETA receptor blockade has been shown to reduce 
plaque formation in an experimental model of atherosclerosis (34), underscoring the adverse 
effects of ET-1 activity on vascular health beyond vasoconstriction.  As such, elevated ET-1-
mediated vasoconstriction may contribute to increased vascular tone and the subsequent risk of 
clinical hypertension, as well as the development and progression of atherosclerotic vascular 
disease in prehypertensive adults. 
A functional consequence of the elevated ET-1 vasoconstrictor tone with prehypertension 
appears to be impaired endothelium-dependent vasodilation.  The prehypertensive adults in the 
present study demonstrated significantly lower (~30%) acetylcholine-mediated vasodilation than 
normotensive adults, confirming that prehypertension is associated with endothelial vasodilator 
dysfunction (10,11).  However, blockade of the ETA receptor restored acetylcholine-mediated 
endothelium-dependent vasodilation in prehypertensive adults to levels similar to that of 
normotensive adults. There are a number of potential mechanisms that may be involved in this 
improvement in endothelium-dependent vasodilation following ETA receptor blockade.  For 
example, it is possible that inhibition of ETA-mediated ET-1 vasoconstriction reversed an 
imbalance in vasoconstrictor and vasodilator influences on the vascular smooth muscle in 
prehypertensive adults, thereby allowing endothelium-derived relaxing factors to act without 
opposition and dilate the vessel appropriately in response to acetylcholine stimulation.  
Alternatively, ETA receptor blockade may improve endothelium-dependent vasodilation by 
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increasing the bioavailability of NO (35).  ET-1 binding to the ETA receptor can reduce NO 
bioavailability directly via inhibition of endothelial NO synthase or indirectly through the 
production of superoxide anion and subsequent inactivation of NO (32,35,36).  Thus, enhanced 
NO bioavailability may underlie the improvement in endothelium-dependent vasodilation with 
ETA receptor blockade in prehypertensive adults.  Unfortunately, in the present study we did not 
address this issue by infusing the endothelial NO synthase antagonist NG-monomethyl-L-
arginine with acetylcholine and BQ-123 to assess the contribution of NO to the observed 
increase in vasodilation. 
It is important to note that the FBF responses observed in the prehypertensive adults in 
the present study are similar to those reported in adults with clinical hypertension (14,15,37).  
For example, Cardillo and colleagues (15) observed greater forearm vasodilation to intra-arterial 
BQ-123 and BQ-788 in hypertensive compared with normotensive adults.  Additionally, ET-1 
receptor blockade improved endothelium-dependent vasodilation in hypertensive adults (14), 
similar to our findings in prehypertensive adults.   These similarities in ET-1-mediated 
vasoconstrictor activity between prehypertensive and hypertensive adults support the notion that 
vascular abnormalities linked with hypertension may already be apparent in the prehypertensive 
state (26).  Indeed, blood pressure in the prehypertensive range is also associated with carotid 
artery intima-media thickening (38).  Taken together, these findings indicate that 
prehypertension is not a benign condition and support recent editorials and reviews advocating 
the implementation of therapeutic interventions at blood pressure levels in the prehypertensive 
range in order to minimize blood pressure-related cardiovascular risk (26,27,39). 
 There are a few experimental considerations regarding the present study that merit 
discussion.  Firstly, given our cross-sectional study design, we cannot discount the possibility 
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that genetic and/or lifestyle behaviors may have influenced our results.  To minimize the 
influence of lifestyle behaviors, we studied sedentary adults who were non-smokers and not 
currently taking any medication that could influence endothelial vasomotor function.  Moreover, 
to isolate the primary influence of blood pressure in the prehypertensive range, we studied adults 
free of cardiometabolic abnormalities that are commonly associated with prehypertension (40) 
and known to influence endothelial function, such as obesity (24), dyslipidemia (41), and 
diabetes (42).  Secondly, the vast majority (~95%) of adults in the present study were Caucasian.  
Thus, any generalizations to other racial groups must be made with caution, given that marked 
elevations in ET-1 vasoconstrictor activity have been reported in African-American adults 
(43,44).  Finally, we did not measure circulating plasma levels of ET-1 in the present study.  The 
physiological significance of plasma ET-1 levels is questionable because ET-1 is predominantly 
(>80%) released abluminally toward the vascular smooth muscle (37,45).  As a result, circulating 
plasma concentrations of the peptide are largely the result of variable spillover into, and 
clearance from, the bloodstream and do not accurately reflect local vascular production or action 
(15).  The measurement of forearm blood flow responses to intra-arterial infusion of ET-1 
receptor antagonists affords a more direct biological assessment of ET-1 system activity in vivo 
(15,25,46). 
 In conclusion, the results of the present study demonstrate that prehypertension is 
associated with enhanced ET-1 vasoconstrictor tone that is mediated by both the ETA and ETB 
receptor subtypes.  In addition, the elevation in ET-1-mediated vasoconstrictor activity 
contributes to diminished endothelium-dependent vasodilation in prehypertensive adults.  
Enhanced ET-1 system activity may be involved in the increased risk of hypertension and 
atherosclerotic vascular disease in prehypertensive adults.  Given the fact that endothelial 
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abnormalities that characterize hypertension appear to be already apparent with blood pressure in 
the prehypertensive range, it may be prudent to more aggressively advocate intervention 
strategies aimed at managing blood pressure and reducing vascular risk in prehypertensive 
adults.
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CONCLUSION 
The primary new findings of the studies presented herein are as follows: 
1) prehypertension is associated with impaired endothelium-dependent vasodilation.  
Compared with normotensive adults, prehypertensive adults exhibited significantly lower 
forearm blood flow responses to the endothelium-dependent vasodilator acetylcholine; 
2) impaired acetylcholine-mediated endothelium-dependent vasodilation with 
prehypertension is mediated, in part, by a reduction in nitric oxide bioactivity.  Co-
infusion of the endothelial nitric oxide synthase inhibitor L-NMMA significantly reduced 
forearm blood flow responses to acetylcholine in normotensive but not prehypertensive 
adults; 
3) prehypertensive adults exhibit elevated endothelin-1 vasoconstrictor tone that is 
mediated by both the ETA and ETB receptor subtypes.  Selective ETA receptor blockade 
elicited a significantly greater vasodilator response in prehypertensive compared with 
normotensive adults.  Furthermore, non-selective ETA and ETB receptor blockade 
produced significantly greater vasodilation in prehypertensive adults than that produced 
by selective ETA antagonism; 
4) the elevation in endothelin-1-mediated vasoconstrictor activity contributes to 
diminished endothelium-dependent vasodilation in prehypertensive adults.  Selective ETA 
receptor blockade increased acetylcholine-mediated endothelium-dependent vasodilation 
in prehypertensive adults to levels similar to that of normotensive adults; 
 
Collectively, these studies indicate that prehypertension is associated with impaired vascular 
endothelial vasomotor function.  These endothelial abnormalities may contribute to the increased 
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risk of clinical hypertension and atherosclerotic vascular disease in prehypertensive adults.  
Given the fact that alterations in endothelial function that characterize clinical hypertension are 
already apparent in adults with prehypertension, it may be necessary to more strictly implement 
interventions aimed at lowering blood pressure and reducing cardiovascular risk at blood 
pressure levels below the traditional cut-off for hypertension. 
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